As the complexity of healthcare increases, it is vitale for senior business executives to gain a comprehensive understanding of key market dynamics to remain competitive. In the continuously evolving landscape of healthcare, the immunosuppressant drugs market bears continued exploration and examination.
Purchasing this market research report equips you with crucial insights into the dynamics affecting the immunosuppressant drug market. Factors such as the growing prevalence of autoimmune diseases, rise in organ transplants, and technological advancements in tissue engineering and organ transplantations are examined in detail. Understanding these key drivers will empower your strategic decision-making, allowing you to capitalize on opportunities and mitigate challenges in a proactive manner.
Furthermore, you will gain a granular understanding of market trends, such as the dominance of the Systemic Autoimmune Disease Segment. This will allow you to align your corporate strategy with the latest developments, ensuring you stay ahead of your competition in this competitive market.
With the addition of further data on regional markets and key industry players, this report is a valuable asset for anyone striving to succeed in the fast-paced and complex world of the immunosuppressant drugs market.
The COVID-19 pandemic had a significant effect on the market. For instance, according to an article published by PubMed Central in April 2022, there was a 16% global reduction in transplant activity during the initial pandemic, resulting in a substantial impact on the waitlisted patient. Reduced organ transplants meant a reduction in the usage of immunosuppressant drugs as well. However, as the pandemic has subsided, the studied market is expected to grow.
Factors such as the growing prevalence of autoimmune diseases, the rise in organ transplants, and technological advancements in tissue engineering and organ transplantations are expected to enhance the market growth.
The increasing prevalence of autoimmune diseases is a major factor that is expected to enhance the market growth. For instance, according to an article updated by the NCBI in April 2022, around 2.5 million people worldwide have multiple sclerosis, and the article also stated that females are three times more prone to develop the illness than males.
Furthermore, according to an article published by MDPI in July 2022, Rheumatoid arthritis (RA) is considered a common autoimmune illness that manifests majorly as chronic, symmetric, and progressive polyarthritis with a global frequency of 0.3-1.0%. This will lead to increased adoption of immunosuppressant drugs for RA, driving market growth.
Product approval is another major factor for market growth. For instance, in February 2022, China’s National Medical Products Administration (NMPA) approved GlaxoSmithKline’s Benlysta for the treatment of adult patients with active lupus nephritis (LN) in China.
While growth is expected, stringent regulatory processes are expected to hinder the market growth.
Immunosuppressant Drugs Market Trends
The Systemic Autoimmune Disease Segment is Expected to Hold a Significant Market Share Over the Forecast PeriodSystemic autoimmune diseases are those where autoantigens can be found in almost any type of cell in the body, for example, DNA or protein complexes. As a result, pathological damage involves many different organs and tissues. The increasing prevalence of systemic autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, psoriasis, and dermatomyositis are expected to boost market growth.
According to an article published by MDPI in July 2022, in India, the prevalence of Rheumatoid Arthritis was around 0.7%, with almost 10 million persons suffering from the disease. People with rheumatoid arthritis experience fatigue on most days, with over 70% experiencing symptoms similar to chronic fatigue syndrome.
Furthermore, according to an article published by the Annals of Rheumatic Diseases in October 2022, women were more likely to have systemic lupus erythematosus (SLE) than men. The article further stated that the global SLE incidence and newly diagnosed population in women are estimated to be 8.82 (2.4 to 25.99) per 100,000 person-years and 0.34 million annually, respectively. At the regional level, the incidence of SLE in women varied from 2.00 (0.27 to 6.22) per 100,000 person-years in central Asia to 22.99 (5.35 to 53.28) per 100,000 person-years in central Europe.
Moreover, key product launches by market players are also expected to boost segment growth. For instance, in January 2021, FDA approved Lupkynis (voclosporin), an oral drug that is indicated for the treatment of adult patients with active lupus nephritis developed by Aurinia Pharmaceuticals. It is a novel, structurally modified calcineurin inhibitor that acts as an immunosuppressant and binds and inhibits calcineurin.
North America is Expected to Hold a Significant Share in the Market Over the Forecast PeriodNorth America is expected to hold a significant market share in the immunosuppressant drugs market due to the increasing prevalence of autoimmune diseases and the rapid rise in the number of organ transplants in this region.
The increasing prevalence of autoimmune diseases in the region is a major factor that is expected to drive market growth. For instance, according to data updated by the National Institute of Environmental Health Sciences in May 2022, collectively autoimmune diseases affected more than 24 million people in the United States, and an additional eight million people had auto-antibodies, blood molecules that indicate a person’s chance of developing autoimmune disease. Moreover, according to data updated by Statistics Canada in December 2021, 6,087,600 people had arthritis in Canada in 2021.
Furthermore, the rising research spending on autoimmune diseases is also expected to boost the development of immunosuppressant drugs to treat these diseases. For instance, according to data updated by NIH in May 2022, an estimated USD 1,021 million was spent on the research of autoimmune diseases in the United States in 2021, and was expected to rise to USD 1,061 million by 2022.
Increasing organ transplants are another factor contributing to the market growth. For instance, according to data from the Organ Procurement and Transplantation Network in January 2022, 41,354 organ transplants were performed in the United States in 2021, an increase of 5.9 percent over the last year, going over 40,000 for the first time.
Immunosuppressant Drugs Industry OverviewThe immunosuppressant drugs market is fragmented and consists of several major players. In terms of market share, a few major players dominate the market. Some of the companies which are currently dominating in the market are Astellas Pharma, Inc, Sanofi (Genzyme), Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc, GlaxoSmithKline Plc, Allergan Plc (Abbvie), Accord Healthcare Ltd (Intas Pharmaceuticals), and Viatris Inc. among others.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Growing Prevalence of Autoimmune Diseases and Rise in the Number of Organ Transplants
4.2.2 Technological Advancements in Tissue Engineering and Organ Transplantations
4.3 Market Restraints
4.3.1 Stringent Regulatory Processes
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Calcineurin Inhibitors
5.1.2 Antiproliferative Agents
5.1.3 mTOR Inhibitor
5.1.5 Other Drug Classes
5.2 By Application
5.2.1 Autoimmune diseases
18.104.22.168 Systemic Autoimmune Disease
22.214.171.124 Localized Autoimmune Disease
5.2.2 Organ transplant
5.2.3 Other Applications
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.3.5 South America
188.8.131.52 Rest of South America
6.1.1 Accord Healthcare Ltd (Intas Pharmaceuticals)
6.1.2 Allergan Plc (Abbvie)
6.1.3 Astellas Pharma, Inc
6.1.4 Bristol-Myers Squibb Company
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 GlaxoSmithKline Plc
6.1.7 Janssen Pharmaceuticals, Inc (Johnson & Johnson)
6.1.8 Viatris Inc.
6.1.9 Novartis AG
6.1.10 Pfizer Inc
6.1.11 Veloxis Pharmaceuticals, Inc. (Asahi Kasei)
6.1.12 Sanofi (Genzyme)
A selection of companies mentioned in this report includes:
- Accord Healthcare Ltd (Intas Pharmaceuticals)
- Allergan Plc (Abbvie)
- Astellas Pharma, Inc
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Janssen Pharmaceuticals, Inc (Johnson & Johnson)
- Viatris Inc.
- Novartis AG
- Pfizer Inc
- Veloxis Pharmaceuticals, Inc. (Asahi Kasei)
- Sanofi (Genzyme)